Heartflow, Inc. Common Stock (HTFL) - Stock Analysis

Last updated: Jul 27, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

HeartFlow (HTFL) has multiple fresh growth catalysts—Aetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000‑patient NAVIGATE‑PCI registry on March 16, 2026—and its stock has surged ~20–30% off the March low, positioning it as a high‑beta, event-driven healthcare IT momentum trade despite ongoing operating losses.

Loading chart data...

Idea window: 3/23/2026 – 3/30/2026Sector: Healthcare

AI Analyst Overview

Last Price
$25.04
Market Cap
$2.52B
1D Return
-2.15%
YTD Return
-14.10%

Loading chart data...

Valuation Metrics

P/E
-92.7
P/B
36.0
P/S
14.3
EV/EBITDA
-40.4
Div Yield

Price Behavior

3.0

Key Price Behavior Insights: • Lower-high pattern • Failed rebounds • Near support Support Level: $24.0–$24.5 Resistance Level: $25.5–$26.0 HTFL is in a clear short-term downtrend over the last month, with lower highs/lows and failed bounces, though near $24.0–$24.5 support could still trigger only a tentative reflex bounce.

downtrend
support

Sentiment & News

7.0

Key News Insights: • Clinical validation • Workflow adoption • Insider sale HeartFlow's news flow is increasingly bullish, driven by strong SCCT validation of its AI coronary plaque analysis, expanding workflow/billing prospects, and broader commercial adoption, with the CEO's share sale as the main offsetting headline.

HeartFlow
AIHealthcare
AI

AI Summary

5.0
Neutral

HTFL now hinges less on clinical promise and more on whether rising revenue, bundled Plaque Staging, and any reimbursement tailwind can convert into durable adoption and operating leverage, because the stock's sharp downtrend and insider sale show the market still wants proof that growth is monetizable, not just scientifically credible.

RevenueGrowth
ExecutionRisk
Reimbursement
AI summary updated 2 days ago

Description

HeartFlow offers a non-invasive diagnostic platform that converts a single coronary CT angiogram into a patient-specific 3D heart model and applies computational fluid dynamics and related analytics to quantify blood flow, arterial narrowing, and plaque characteristics. Founded in 2007 and based in Mountain View, California, the company distributes its technology globally to support clinical assessment and management of coronary artery disease.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Mar 23Mar 30HTFLHeartflow, Inc. Common Stock
HeartFlow (HTFL) has multiple fresh growth catalysts—Aetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000‑patient NAVIGATE‑PCI registry on March 16, 2026—and its stock has surged ~20–30% off the March low, positioning it as a high‑beta, event-driven healthcare IT momentum trade despite ongoing operating losses.
Closed-11.0%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.